asco 2023 highlights on erdafitinib in metastatic urothelial cancer with select fgfr alterations
Published 1 year ago • 836 plays • Length 4:47Download video MP4
Download video MP3
Similar videos
-
23:51
bladder cancer conference highlights from asco 2023
-
11:42
fgfr inhibitors in bladder cancer: testing, screening and highlights from asco 2020
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
1:27
highlights in kidney and bladder cancer at asco 2023
-
47:21
asco 2023: highlights and analysis
-
2:59
effectively target fgfr with erdafitinib for bladder cancer? highlights from asco 2018 (bmic-050)
-
6:10
asco® gu urothelial cancer study roundup: ev, atezolizumab, erdafitinib, and more
-
1:33
hot topics in bladder cancer from asco gu 2023
-
4:40
asco 2023 highlights on the mirasol trial in pt-resistant adv. high-grade epithelial ovarian cancer
-
2:15
asco gu 2023: highlights in prostate cancer
-
8:50
asco genitourinary cancer updates: 2023 review and renew lake tahoe
-
0:41
asco gi 2023 highlights
-
20:39
kidney cancer conference highlights from asco gu 2023
-
1:10
highlights in bladder cancer from asco 2022
-
0:59
genitourinary cancer updates at asco 2023
-
3:00
exclusive highlights in genitourinary cancer at asco 2023
-
1:44
highlights in renal cell carcinoma from asco gu 2023 and what to look out for in the future
-
1:10
asco 2022: genitourinary cancer highlights